Apogee will report Part A 52-week data from the Phase 2 APEX trial of zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis on March 23, 2026. Following the announcement, we will host a conference call and webcast at 8:00 a.m. ET tomorrow morning to discuss the results. Visit the link below to access the live webcast. https://lnkd.in/e_HTqZEG
Jessica Davis
1mo
Very impressive. I hope life is treating you well Jeff! I miss working with you!
Can’t wait to see what you have to say… 👀